@article{3031153,
    title = "The T2-FLAIR Mismatch Sign as an Imaging Indicator of IDH-Mutant, 1p/19q
Non-Codeleted Lower Grade Gliomas: A Systematic Review and Diagnostic
Accuracy Meta-Analysis",
    author = "Adamou, Antonis and Beltsios, Eleftherios T. and Papanagiotou, and Panagiotis",
    journal = "DIAGNOSTIC ONCOLOGY",
    year = "2021",
    volume = "11",
    number = "9",
    publisher = "MDPI",
    doi = "10.3390/diagnostics11091620",
    keywords = "T2-FLAIR mismatch sign; glioma; astrocytoma; diagnostic accuracy;
systematic review; meta-analysis",
    abstract = "The study’s objective was the evaluation of the diagnostic accuracy of
the T2-FLAIR mismatch sign in terms of diagnosing IDH-mutant
non-codeleted (IDHmut-Noncodel) lower grade gliomas (LGG) of the brain.
We searched the MEDLINE, Scopus and Cochrane Central databases. The last
database search was performed on 12 April 2021. Studies that met the
following were included: MRI scan assessing the presence of T2-FLAIR
mismatch sign, and available IDH mutation and 1p/19q codeletion status.
The quality of studies was assessed using the QUADAS-2 tool. Twelve
studies involving 14 cohorts were included in the quantitative analysis.
The diagnostic odds ratio [DOR (95% confidence interval; CI)] was
estimated at 34.42 (20.95, 56.56), P-z < 0.01. Pooled sensitivity and
specificity (95% CI) were estimated at 40% (31-50%; P-z = 0.05) and
97% (93-99%; P-z < 0.01), respectively. The likelihood ratio (LR; 95%
CI) for a positive test was 11.39 (6.10, 21.29; P-z < 0.01) and the LR
(95% CI) for a negative test was 0.40 (0.24, 0.65; P-z < 0.01).The
T2-FLAIR mismatch sign is a highly specific biomarker for the diagnosis
of IDHmut-Noncodel LGGs. However, the test was found positive in some
other tumors and had a high number of false negative results. The
diagnostic accuracy of the mismatch sign might be improved when combined
with further imaging parameters."
}